|
Funding Body |
Project Title |
Date Awarded |
Role in Grant |
Co-applicants |
|
North Bristol NHS Trust |
Flexibility and sustainability funding for NIHR pump priming activities |
01/01/2008 |
Principal Investigator |
AP MacGowan, AM Lovering |
|
Western CLRN |
Infrastructure funding |
01/01/2008 |
Principal Investigator |
AP MacGowan, AM Lovering |
|
Western CLRN |
Key support for funding equipment |
01/01/2008 |
Principal Investigator |
AM Lovering, KE Bowker |
|
NIHR |
Programme Grant: Blood stream infection: focus on outcomes |
09/10/2008 |
Principal Investigator |
AP MacGowan |
|
NIHR-HTA |
HTA: The diagnosis of urinary tract infection in young children (DUTY) study |
01/01/2009 |
Co-applicant |
AP MacGowan |
| EU/European CDC | Development of a European susceptibility testing method | 01/01/2008 | Co-applicant | AP MacGowan |
| North Bristol NHS Trust | Flexibility and sustainability funding for NIHR pump priming activities | 01/01/2009 | Principal Investigator | AP MacGowan, AM Lovering |
| NISCHR | Research group: Microbiology and Infection Translational Research Group | 01/01/2010 | Co-applicant | AP MacGowan, AM Lovering |
| Cerexa | Pharmacodynamic assessment of the combination of ceftaroline plus NXL 104 against wild type and multi-resistant Enterobacteriacaea studied in an in vitro pharmacokinetic infection model | 01/01/2009 | Principal Investigator | AP MacGowan, KE Bowker |
| Protez Pharmaceuticals Inc | Pharmacodynamic assessment of PZ601 against Staphylococcus aureus and Enterobacteriacae: antibacterial effects of simulated human doses and assessment of T>MIC relationships | 01/02/2008 | Principal Investigator | AP MacGowan, KE Bowker |
| Bayer Schering Healthcare | Studies on sequential fluoroquinolone dosing in an in vitro pharmacokinetic model of infection: impact on antibacterial effect and risk of emergence of resistance | 01/04/2007 | Principal Investigator | AP MacGowan, KE Bowker |
| Astellas Pharma Europe Ltd | Comparative pharmacodynamics of telavancin, daptomycin, linezolid, vancomycin and teicoplanin studied in an in vitro pharmacokinetic model of infection | 01/08/2007 | Principal Investigator | AP MacGowan, KE Bowker |
| Johnson & Johnson | Pharmacodynamic assessment of doripenem and imipenem against Pseudomonas aeruginosa and Acinetobacter species: impact of T>MIC | 01/07/2007 | Principal Investigator | AP MacGowan, KE Bowker |
| Basilea Pharmaceutica | In vitro study to investigate the potency of new dihydrofolate reductase inhibitors against clinical Gram positive pathogens | 01/05/2007 | Principal Investigator | AP MacGowan, KE Bowker |
| Mayne Pharma plc | A Phase 1 randomised double blind cross over study to compare the pharmacokinetic/pharmacodynamic and safety characteristics of targocid with Mayne teicoplanin administered as single iv doses in healthy volunteers | 01/07/2006 | Principal Investigator | AP MacGowan, AM Lovering |
| Hoffman La Roche | The pharmacodynamics of the antibacterial effect and emergence of resistance to R04906463/CS-023/tomopenem in an in vitro pharmacokinetic model of S.aureus infection | 01/05/2005 | Principal Investigator | AP MacGowan, KE Bowker |
| Basilea Pharmaceutica | The in vitro potency of a novel Blactam/Blactamase inhibitor combination against P.aeruginosa, Enterobacter cloacae, Klebsiella Pneumoniae and E.coli using an in vitro pharmacokinetic model | 01/07/2006 | Principal Investigator | AP MacGowan, KE Bowker |
| Basilea Pharmaceutica | In vitro study to investigate the potency of BAL 30072 against clinical strains of Enterobacter species and Gram negative rods with defined resistance mechanisms | 01/10/2006 | Principal Investigator | AP MacGowan, KE Bowker |
| Cubist Pharmaceuticals | Determination of daptomycin and vancomycin MIC, MBC and kill curves on US MRSA isolates | 01/08/2006 | Co-Principal Investigator | AP MacGowan, TR Walsh |
| Merck Sharp & Dohme | The antibacterial effects of ceftriaxone, ertapenem and piperacillin-tazobactam against extended spectrum Blactamase strains of Enterobacteriacae in an in vitro pharmacokinetic model | 01/01/2005 | Principal Investigator | AP MacGOwan, AR Noel, KE Bowker |
| GR Micro Ltd | Comparative pharmacodynamics of daptomycin, vancomycin and teicoplanin in an in vitro pharmacokinetic model of infection | 01/02/2005 | Principal Investigator | AP MacGowan, KE Bowker, AR Noel |
| European Union DGSANCO/European CDC | Antibiotic susceptibility proposal 790806 | 01/01/2005 | Co-applicant | AP MacGowan |
| Department of Health | Sentinel and population surveillance of Panton-Valentine leucocidin-positive S.aureus and community acquired MRA | 01/06/2007 | Co-Principal Investigator | AM Lovering, AP MacGowan |
| National School for Primary Care Research, Department of Health | Primary Care antibiotic prescribing and antimicrobial resistance (PCAAR) | 01/02/2007 | Co-Principal Investigator | AM Lovering, AP MacGowan |
| Showering Fund | An investigation of the reservoir of antibiotic resistance genes by the commercial bacteria of healthy community volunteers and how this impacts on the prevalence of antibiotic resistance in bacteria associated with UTI | 01/07/2008 | Principal Investigator | AM Lovering |
| North Bristol NHS Trust Research Foundation | Determination of protein binding of vancomycin in a general hospital patient population | 01/06/2007 | Principal Investigator | AM Lovering |
| North Bristol NHS Trust Research Foundation | An evaluation of the Bronkotest system for identification of respiratory infection | 01/06/2007 | Principal Investigator | AM Lovering |
| Basilea | The in vitro activity of BAL 30072 using simulated human serum pharmacokinetics against multiresistant Pseudomonas aeruginosa | 01/01/2009 | Co-Principal Investigator | KE Bowker |